CorMedix Inc. (CRMD)

7.71
0.06 0.77
AMEX : Health Technology
Prev Close 7.77
Open 7.71
Day Low/High 7.63 / 8.10
52 Wk Low/High 1.03 / 13.70
Volume 273.03K
Avg Volume 480.60K
Exchange AMEX
Shares Outstanding 23.80M
Market Cap 189.71M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

The Top-Performing Biotech Stock During a Sizzling First Quarter

The Top-Performing Biotech Stock During a Sizzling First Quarter

That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.

Interesting CRMD Call Options For May 15th

Interesting CRMD Call Options For May 15th

Investors in CorMedix Inc saw new options become available this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRMD options chain for the new May 15th contracts and identified the following call contract of particular interest.

A Steady but Sloppy Day

Awaiting Yellen, but some churn wouldn't hurt.

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

3 Biotech Stocks Under $10 to Trade

3 Biotech Stocks Under $10 to Trade

Keep your eye on these under-$10 biotech stocks.

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.

CorMedix Receives CE Mark For Neutrolin® Catheter Lock Solution

CorMedix Receives CE Mark For Neutrolin® Catheter Lock Solution

CorMedix Inc. (NYSE MKT: CRMD) today announced that it has received CE Mark approval for Neutrolin®, a catheter lock solution, for patients with central venous catheters on hemodialysis secondary to advanced...

CorMedix Reports Year End 2012 Financial Results

CorMedix Reports Year End 2012 Financial Results

CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces its financial...

CorMedix Granted Extension Of NYSE MKT Listing

CorMedix Granted Extension Of NYSE MKT Listing

CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces the receipt ...

CorMedix Signs Sales And Marketing Agreement With MKM Co-Pharma, Bolsters Commercial Management Team To Ready Neutrolin® Catheter Lock Solution For European Market

CorMedix Signs Sales And Marketing Agreement With MKM Co-Pharma, Bolsters Commercial Management Team To Ready Neutrolin® Catheter Lock Solution For European Market

CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced today that it has signed ...

CorMedix: Final Closing Of 2012 Financing

CorMedix: Final Closing Of 2012 Financing

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, held the second and ...

CorMedix Successfully Completes And Passes ISO 13485 Certification Audit

CorMedix Successfully Completes And Passes ISO 13485 Certification Audit

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced today...

CorMedix: Initial Close On Financing And Extension Granted To Regain Compliance With NYSE Amex Listing Standards

CorMedix: Initial Close On Financing And Extension Granted To Regain Compliance With NYSE Amex Listing Standards

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, held the initial ...

CorMedix: Granted Extension Of NYSE Amex Listing

CorMedix: Granted Extension Of NYSE Amex Listing

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, announces the receipt...

CorMedix Provides An Update On CE Marking Process For Neutrolin® In The EU

CorMedix Provides An Update On CE Marking Process For Neutrolin® In The EU

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, announces the receipt...

CorMedix Receives NYSE Amex Notice Of Delisting For Non-Compliance

CorMedix Receives NYSE Amex Notice Of Delisting For Non-Compliance

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), is a development stage pharmaceutical and medical device company that seeks to in-license, develop and commercialize therapeutic products for the treatment of ...

CorMedix Reports Year End 2011 Financial Results

CorMedix Reports Year End 2011 Financial Results

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), is a development stage pharmaceutical and medical device company that seeks to in-license, develop and commercialize therapeutic products for the treatment of ...

CorMedix Provides Year End 2011 Update

CorMedix Provides Year End 2011 Update

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its ...

CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy To Board Of Directors

CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy To Board Of Directors

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced the ...

CorMedix Reports Third Quarter 2011 Results

CorMedix Reports Third Quarter 2011 Results

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced its ...

CorMedix To Host Conference Call On Recent Developments

CorMedix To Host Conference Call On Recent Developments

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that a...

CorMedix Announces Strategic Changes

CorMedix Announces Strategic Changes

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has...

CorMedix Announces FDA Designation For Neutrolin (CRMD003)

CorMedix Announces FDA Designation For Neutrolin (CRMD003)

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that...

CorMedix To Present At The Rodman & Renshaw Annual Global Investment Conference

CorMedix To Present At The Rodman & Renshaw Annual Global Investment Conference

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it is...

CorMedix Announces Amended Agreement For CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Announces Amended Agreement For CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has...

CorMedix Announces Appointment Of Steven W. Lefkowitz To Board Of Directors

CorMedix Announces Appointment Of Steven W. Lefkowitz To Board Of Directors

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced the ...

CorMedix Reports Second Quarter 2011 Results

CorMedix Reports Second Quarter 2011 Results

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced its ...

CorMedix Submits Design Dossier For Neutrolin® (CRMD003) To Start European Approval Process

CorMedix Submits Design Dossier For Neutrolin® (CRMD003) To Start European Approval Process

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced today that...

TheStreet Quant Rating: D- (Sell)